Dr. Andrew Makin, MD. Global Vice President of Medical Affairs at Oxford Immunotec, makers of The T-SPOT.COVID test discusses T-cell testing and how it can provide vital medical insights as we continue our journey through this pandemic.
Dr Makin first qualified as a mechanical engineer in 1990 but had a change of career and medicine qualified in Birmingham in the United Kingdom in 1996. After a brief period as a surgeon in the NHS, joined the pharmaceutical industry.
Dr Makin has worked across wide range of therapeutic areas, including cardiovascular, mental health and inherited renal disease before settling on his current are of infectious disease. His areas of functional expertise within the industry including medical affairs, drug safety, regulatory affairs and clinical development and has been involved in bringing medicines to patients such as the first treatment for Autosomal Dominant Polycystic Kidney Disease, and inherited kidney disease.
Dr Makin joined the Oxford Immunotec Ltd team in 2020 just as the COVID-19 pandemic began and has been working on the company’s offering to aid physicians and researchers in accumulating knowledge in COVID-19 and bringing related clinical tests to the public. He has been instrumental in initiatives to increase the creation and dissemination of knowledge of T cells in this disease.
As well as degrees in medicine and engineering, Dr Makin also has a business degree, a research doctorate in molecular biology, fellowship of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of England.